Pfizer's Ibrance conquers new breast cancer territory

Pfizer's new CDK4 and 6 inhibitor Ibrance (palbociclib) has hit its progression-free survival primary endpoint in the Phase III PALOMA-3 study in a new breast cancer population, stopping the trial early.